Cargando…
Early and late recurrent cardiovascular events among high‐risk patients with an acute coronary syndrome: Meta‐analysis of phase III studies and implications on trial design
BACKGROUND: Despite low‐density lipoprotein cholesterol‐lowering therapies and other standard‐of‐care therapy, there remains a substantial residual atherosclerotic risk among patients with an acute coronary syndrome (ACS). This study aims to estimate the risk of early and late recurrent major advers...
Autores principales: | Chi, Gerald, Lee, Jane J., Kazmi, Syed H. A., Fitzgerald, Clara, Memar Montazerin, Sahar, Kalayci, Arzu, Korjian, Serge, Heise, Mark, Deckelbaum, Lawrence I., Libby, Peter, Bhatt, Deepak L., Gibson, C. Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922536/ https://www.ncbi.nlm.nih.gov/pubmed/35019162 http://dx.doi.org/10.1002/clc.23773 |
Ejemplares similares
-
Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Lee, Jane J., et al.
Publicado: (2021) -
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future
por: Kalayci, Arzu, et al.
Publicado: (2022) -
Independent and incremental prognostic value of D-dimer in hospitalized COVID-19 patients
por: Chi, Gerald, et al.
Publicado: (2021) -
Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients
por: Lee, Jane J, et al.
Publicado: (2021) -
Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction
por: Korjian, Serge, et al.
Publicado: (2023)